Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
HBI-002 by Hillhurst Biopharmaceuticals for Sickle Cell Disease: Likelihood of Approval
HBI-002 is under clinical development by Hillhurst Biopharmaceuticals and currently in Phase I for Sickle Cell Disease. According to GlobalData,...